Sangamo Therapeutics logo

Sangamo Therapeutics Share Price Today

(NASDAQ: SGMO)

Sangamo Therapeutics share price is $0.99 & ₹86.34 as on 12 Mar 2025, 19.45 hrs IST

$0.99

Market is closed - opens 7 PM, 12 Mar 2025

View live Sangamo Therapeutics share price in Dollar and Rupees. Guide to invest in Sangamo Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Sangamo Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Sangamo Therapeutics share price movements

  • Today's Low: $0.94
    Today's High: $1.03

    Day's Volatility :8.63%

  • 52 Weeks Low: $0.30
    52 Weeks High: $3.18

    52 Weeks Volatility :90.44%

Sangamo Therapeutics (SGMO) Returns

PeriodSangamo Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-48.87%
3.6%
0.0%
6 Months
17.55%
-6.3%
0.0%
1 Year
15.19%
-0.7%
0.0%
3 Years
-81.03%
13.3%
-10.6%

Sangamo Therapeutics (SGMO) Key Statistics

in dollars & INR

Previous Close
$0.992
Open
$0.9849
Today's High
$1.04
Today's Low
$0.9921
Market Capitalization
$563.2M
Today's Volume
$3.2M
52 Week High
$3.179
52 Week Low
$0.304
Revenue TTM
$12.3M
EBITDA
$-185.0M
Earnings Per Share (EPS)
$-1.24
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-194.05%

How to invest in Sangamo Therapeutics Stock (SGMO) from India?

It is very easy for Indian residents to invest directly in Sangamo Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Sangamo Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Sangamo Therapeutics or SGMO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Sangamo Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Sangamo Therapeutics shares which would translate to 0.881 fractional shares of Sangamo Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Sangamo Therapeutics, in just a few clicks!

Returns in Sangamo Therapeutics (SGMO) for Indian investors in Rupees

The Sangamo Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Sangamo Therapeutics investment value today

Current value as on today

₹1,20,518

Returns

₹20,518

(+20.52%)

Returns from Sangamo Therapeutics Stock

₹15,116 (+15.12%)

Dollar Returns

₹5,402 (+5.4%)

Indian investors sentiment towards Sangamo Therapeutics (SGMO)

-52%

Period: Feb 9, 2025 to Mar 11, 2025. Change in 30 Days versus previous period

Search interest for Sangamo Therapeutics Stock from India on INDmoney has decreased by -52% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Sangamo Therapeutics

  • Vanguard Group Inc

    4.49%

  • Wasatch Advisors LP

    4.42%

  • BlackRock Inc

    2.49%

  • State Street Corp

    2.41%

  • Renaissance Technologies Corp

    1.48%

  • Millennium Management LLC

    1.31%

Analyst Recommendation on Sangamo Therapeutics

Buy

    66%Buy

    33%Hold

    0%Sell

Based on 15 Wall street analysts offering stock ratings for Sangamo Therapeutics(by analysts ranked 0 to 5 stars)

Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
5
5
5
Sell
0
0
0

Analyst Forecast on Sangamo Therapeutics Stock (SGMO)

What analysts predicted

Upside of 384.85%

Target:

$4.80

Current:

$0.99

Insights on Sangamo Therapeutics Stock (Ticker Symbol: SGMO)

  • Price Movement

    In the last 7 days, SGMO stock has moved up by 13.4%

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 356.0K → 49.41M (in $), with an average increase of 99.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 6 quarters, -114.50M → 10.67M (in $), with an average increase of 116.0% per quarter

  • SGMO vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.8% return, outperforming this stock by 47.6%

  • SGMO vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 54.1% return, outperforming this stock by 136.4%

  • Price to Sales

    ForSGMO every $1 of sales, investors are willing to pay $15.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.6 for every $1 of sales.

SGMO Sangamo Therapeutics Financials in INR & Dollars

FY18Y/Y Change
Revenue
$84.5M
↑ 130.95%
Net Income
$-68.3M
↑ 25.23%
Net Profit Margin
-80.91%
↑ 68.32%
FY19Y/Y Change
Revenue
$102.4M
↑ 21.29%
Net Income
$-75.8M
↑ 10.95%
Net Profit Margin
-74.02%
↑ 6.89%
FY20Y/Y Change
Revenue
$118.2M
↑ 15.39%
Net Income
$-121.1M
↑ 59.75%
Net Profit Margin
-102.48%
↓ 28.46%
FY21Y/Y Change
Revenue
$110.7M
↓ 6.34%
Net Income
$-178.3M
↑ 47.2%
Net Profit Margin
-161.06%
↓ 58.58%
FY22Y/Y Change
Revenue
$111.3M
↑ 0.54%
Net Income
$-192.3M
↑ 7.84%
Net Profit Margin
-172.76%
↓ 11.7%
FY23Y/Y Change
Revenue
$176.2M
↑ 58.34%
Net Income
$-257.8M
↑ 34.09%
Net Profit Margin
-146.3%
↑ 26.46%
Q2 FY23Q/Q Change
Revenue
$6.8M
↓ 95.67%
Net Income
$-114.5M
↓ 641.84%
Net Profit Margin
-1.7K%
↓ 1688.67%
Q3 FY23Q/Q Change
Revenue
$9.4M
↑ 37.5%
Net Income
$-104.2M
↓ 9.03%
Net Profit Margin
-1.1K%
↑ 566.94%
Q4 FY23Q/Q Change
Revenue
$2.0M
↓ 78.27%
Net Income
$-60.3M
↓ 42.11%
Net Profit Margin
-3.0K%
↓ 1844.44%
Q1 FY24Q/Q Change
Revenue
$481.0K
↓ 76.44%
Net Income
$-49.1M
↓ 18.59%
Net Profit Margin
-10.2K%
↓ 7252.82%
Q2 FY24Q/Q Change
Revenue
$356.0K
↓ 25.99%
Net Income
$-36.1M
↓ 26.4%
Net Profit Margin
-10.1K%
↑ 57.3%
Q3 FY24Q/Q Change
Revenue
$49.4M
↑ 13779.78%
Net Income
$10.7M
↓ 129.54%
Net Profit Margin
21.6%
↑ 10169.91%
FY18Y/Y Change
Profit
$84.5M
↑ 130.95%
FY19Y/Y Change
Profit
$102.4M
↑ 21.29%
FY20Y/Y Change
Profit
$118.2M
↑ 15.39%
FY21Y/Y Change
Profit
$110.7M
↓ 6.34%
FY22Y/Y Change
Profit
$111.3M
↑ 0.54%
FY23Y/Y Change
Profit
$-45.3M
↓ 140.72%
Q2 FY23Q/Q Change
Profit
$2.6M
↓ 98.33%
Q3 FY23Q/Q Change
Profit
$-113.0K
↓ 104.38%
Q4 FY23Q/Q Change
Profit
$-940.0K
↑ 731.86%
Q1 FY24Q/Q Change
Profit
$-2.0M
↑ 117.55%
Q2 FY24Q/Q Change
Profit
$-2.2M
↑ 8.41%
Q3 FY24Q/Q Change
Profit
$49.4M
↓ 2328.78%
FY18Y/Y Change
Operating Cash Flow
$37.2M
↑ 232.34%
Investing Cash Flow
$-178.1M
↑ 120.14%
Financing Cash Flow
$231.7M
↑ 137.67%
FY19Y/Y Change
Operating Cash Flow
$-144.4M
↓ 488.68%
Investing Cash Flow
$-59.8M
↓ 66.42%
Financing Cash Flow
$142.0M
↓ 38.7%
FY20Y/Y Change
Operating Cash Flow
$169.9M
↓ 217.64%
Investing Cash Flow
$-271.6M
↑ 354.22%
Financing Cash Flow
$153.1M
↑ 7.79%
FY21Y/Y Change
Operating Cash Flow
$-233.3M
↓ 237.31%
Investing Cash Flow
$248.2M
↓ 191.37%
Financing Cash Flow
$32.9M
↓ 78.54%
FY22Y/Y Change
Operating Cash Flow
$-223.6M
↓ 4.13%
Investing Cash Flow
$59.3M
↓ 76.11%
Financing Cash Flow
$84.7M
↑ 157.65%
Q2 FY23Q/Q Change
Operating Cash Flow
$-60.7M
↓ 8.43%
Investing Cash Flow
$42.5M
↑ 18.86%
Financing Cash Flow
$6.5M
↓ 18.53%

Sangamo Therapeutics Technicals Summary

Sell

Neutral

Buy

Sangamo Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Sangamo Therapeutics (SGMO) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sangamo Therapeutics, Inc. logo
Sangamo Therapeutics, Inc.
-14.49%
17.55%
15.19%
-81.03%
-90.74%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.
4.03%
-37.08%
-26.01%
9.41%
54.26%
Beone Medicines Ltd logo
Beone Medicines Ltd
11.85%
16.37%
50.05%
67.46%
69.92%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated
3.91%
2.86%
18.4%
102.06%
121.11%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.
-12.89%
-8.85%
62.8%
57.27%
135.05%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sangamo Therapeutics, Inc. logo
Sangamo Therapeutics, Inc.
NA
NA
0.0
-0.48
-1.94
-0.58
NA
0.47
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.
18.45
18.45
1.04
42.83
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
Beone Medicines Ltd
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated
32.84
NA
1.42
18.06
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sangamo Therapeutics, Inc. logo
Sangamo Therapeutics, Inc.
Buy
$563.2M
-90.74%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.
Buy
$80.1B
54.26%
18.45
31.07%
Beone Medicines Ltd logo
Beone Medicines Ltd
NA
$27.4B
69.92%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals Incorporated
Buy
$125.4B
121.11%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.
Buy
$31.6B
135.05%
NA
-12.37%

About Sangamo Therapeutics

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.
Organization
Sangamo Therapeutics
Employees
405
CEO
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Industry
Health Technology

Management People of Sangamo Therapeutics

NameTitle
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
CEO, President & Director
Ms. Prathyusha Duraibabu CPA, M.B.A.
Senior VP, CFO & Principal Accounting Officer
Dr. Nathalie Dubois-Stringfellow Ph.D.
Senior VP & Chief Development Officer
Mr. Gregory Davis Ph.D.
Head of Research & Technology
Ms. Louise Wilkie
Head of Corporate Communications & Investor Relations
Mr. Scott B. Willoughby
Senior VP, General Counsel & Corporate Secretary
Mr. Phillip Ramsey
Head of Technical Operations
Ms. Stephanie J. Seiler CLP
VP and Head of Business Development & Alliance Management
Mr. David Ojala
Scientist II - Discovery & Translational Research

Important FAQs about investing in SGMO Stock from India :

What is Sangamo Therapeutics share price today?

Sangamo Therapeutics share price today stands at $0.99, Open: $0.98 ; Previous Close: $0.99 ; High: $1.03 ; Low: $0.94 ; 52 Week High: $3.18 ; 52 Week Low: $0.30.

The stock opens at $0.98, after a previous close of $0.99. The stock reached a daily high of $1.03 and a low of $0.94, with a 52-week high of $3.18 and a 52-week low of $0.30.

Can Indians buy Sangamo Therapeutics shares?

Yes, Indians can invest in the Sangamo Therapeutics (SGMO) from India.

With INDmoney, you can buy Sangamo Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Sangamo Therapeutics at zero transaction cost.

How can I buy Sangamo Therapeutics shares from India?

It is very easy to buy Sangamo Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Sangamo Therapeutics (SGMO) be purchased?

Yes, you can buy fractional shares of Sangamo Therapeutics with INDmoney app.

What are the documents required to start investing in Sangamo Therapeutics stocks?

To start investing in Sangamo Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Sangamo Therapeutics Stock (SGMO)?

Today’s highest price of Sangamo Therapeutics (SGMO) is $1.03.

Today’s lowest price of Sangamo Therapeutics (SGMO) is $0.94.

What is today's market capitalisation of Sangamo Therapeutics?

Today's market capitalisation of Sangamo Therapeutics SGMO is 563.2M

What is the 52 Week High and Low Range of Sangamo Therapeutics Stock (SGMO)?

  • 52 Week High

    $3.18

  • 52 Week Low

    $0.30

What are the historical returns of Sangamo Therapeutics (SGMO)?

  • 1 Month Returns

    -14.49%

  • 3 Months Returns

    17.55%

  • 1 Year Returns

    15.19%

  • 5 Years Returns

    -90.74%

Who is the Chief Executive Officer (CEO) of Sangamo Therapeutics ?

Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. is the current Chief Executive Officer (CEO) of Sangamo Therapeutics.